Potassium channel blocker, 4-aminopyridine-3-methanol, restores axonal conduction in spinal cord of an animal model of multiple sclerosis

Experimental Neurology

Volumn 227, Issue 1, 2011, Pages 232-235

  Leung, Gary ^a   Sun, Wenjing ^a   Brookes, Sarah ^a   Smith, Daniel ^b   Shi, Riyi ^a,c  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Compound action potential; Conduction block; EAE; Multiple sclerosis; Myelin damage; Potassium channel

Indexed keywords

4 AMINOPYRIDINE 3 METHANOL; POTASSIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEMYELINATION; MOUSE; MULTIPLE SCLEROSIS; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD;

ACTION POTENTIALS; AMINOPYRIDINES; ANIMALS; AXONS; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEURAL CONDUCTION; NEUROFILAMENT PROTEINS; PEPTIDE FRAGMENTS; POTASSIUM CHANNEL BLOCKERS; REACTION TIME; SPINAL CORD;

EID: 78650940908     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.11.004     Document Type: Article

References (27)

1. Blight A.R. Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury. Cent. Nerv. Syst. Trauma. 1985, 2:299-315.
2. Blight A.R. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res. Bull. 1989, 22:47-52.
3. Blight A.R., Toombs J.P., Bauer M.S., Widmer W.R. The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial. J. Neurotrauma 1991, 8:103-119.
4. Chiu S.Y., Ritchie J.M. Potassium channels in nodal and internodal axonal membrane of mammalian myelinated fibres. Nature 1980, 284:170-171.
5. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
6. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
7. Goodman A.D., Brown T.R., Krupp L.B., Schapiro R.T., Schwid S.R., Cohen R., Marinucci L.N., Blight A.R. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009, 373:732-738.
8. Haghighi S.S., Pugh S.L., Perez-Espejo M.A., Oro J.J. Effect of 4-aminopyridine in acute spinal cord injury. Surg. Neurol. 1995, 43:443-447.
9. Hayes K.C., Poter P.J., Wolfe D.L., Hsieh J.T.C., Delaney G.A., Blight A.R. 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury. J. Neurotrauma 1994, 11:433-446.
10. Jensen J.M., Shi R. Effects of 4-aminopyridine on stretched mammalian spinal cord: the role of potassium channels in axonal conduction. J. Neurophysiol. 2003, 90:2334-2340.
11. Kalyvas A., David S. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron 2004, 41:323-335.
12. Karimi-Abdolrezaee S., Eftekharpour E., Fehlings M.G. Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma. Eur. J. Neurosci. 2004, 19:577-589.
13. Korenke A.R., Rivey M.P., Allington D.R. Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Ann. Pharmacother. 2008, 42:1458-1465.
14. Nashmi R., Jones O.T., Fehlings M.G. Abnormal axonal physiology is associated with altered expression and distribution of Kv1.1 and Kv1.2K+ channels after chronic spinal cord injury. Eur. J. Neurosci. 2000, 12:491-506.
15. Pena F., Tapia R. Relationships among seizures, extracellular amino acid changes, and neurodegeneration induced by 4-aminopyridine in rat hippocampus: a microdialysis and electroencephalographic study. J. Neurochem. 1999, 72:2006-2014.
16. Pena F., Tapia R. Seizures and neurodegeneration induced by 4-aminopyridine in rat hippocampus in vivo: role of glutamate- and GABA-mediated neurotransmission and of ion channels. Neuroscience 2000, 101:547-561.
17. Potter P.J., Hayes K.C., Segal J.L., Hsieh J.T., Brunnemann S.R., Delaney G.A., Tierney D.S., Mason D. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J. Neurotrauma 1998, 15:837-849.
18. Sherratt R.M., Bostock H., Sears T.A. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980, 283:570-572.
19. Shi R., Blight A.R. Compression injury of mammalian spinal cord in vitro and the dynamics of action potential conduction failure. J. Neurophysiol. 1996, 76:1572-1580.
20. Shi R., Blight A.R. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997, 77:553-562.
21. Shi R., Whitebone J. Conduction deficits and membrane disruption of spinal cord axons as a function of magnitude and rate of strain. J. Neurophysiol. 2006, 95:3384-3390.
22. Shi R., Kelly T.M., Blight A.R. Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine. Exp. Neurol. 1997, 148:495-501.
23. Stork C.M., Hoffman R.S. Characterization of 4-aminopyridine in overdose. Clin. Toxicol. 1994, 32:583-587.
24. Sun W., Smith D., Fu Y., Cheng J.X., Bryn S., Borgens R., Shi R. Novel potassium channel blocker, 4-AP-3-MeOH, inhibits fast potassium channels and restores axonal conduction in injured guinea pig spinal cord white matter. J. Neurophysiol. 2010, 103:469-478.
25. Totoiu M.O., Keirstead H.S. Spinal cord injury is accompanied by chronic progressive demyelination. J. Comp. Neurol. 2005, 486:373-383.
26. Waxman S.G. Demyelination in spinal cord injury and multiple sclerosis: what can we do to enhance functional recovery?. J. Neurotrauma 1992, 9:S105-S117. Suppl.
27. Waxman S.G., Utzschneider D.A., Kocsis J.D. Enhancement of action potential conduction following demyelination: experimental approaches to restoration of function in multiple sclerosis and spinal cord injury. Prog. Brain Res. 1994, 100:233-243.